134 related articles for article (PubMed ID: 25326)
1. Characterization of impurities in sulfasalazine.
Zalipsky JJ; Patel DM; Reavey-Cantwell NH
J Pharm Sci; 1978 Mar; 67(3):387-91. PubMed ID: 25326
[TBL] [Abstract][Full Text] [Related]
2. Improved method for salicylazosulfapyridine analysis and partial characterization of impurities in commercial salicylazosulfapyridine.
Stone JC; Gorby R
J Pharm Sci; 1974 Aug; 63(8):1296-8. PubMed ID: 4152910
[No Abstract] [Full Text] [Related]
3. Liquid chromatographic determination of sulfasalazine in tablets and bulk powder.
Egli KL
J Assoc Off Anal Chem; 1985; 68(4):803-6. PubMed ID: 2863249
[TBL] [Abstract][Full Text] [Related]
4. Isolation and identification of three potential impurities of pholcodine bulk drug substance.
Denk OM; Gray AI; Skellern GG; Watson DG
J Pharm Pharmacol; 2000 Jul; 52(7):819-29. PubMed ID: 10933132
[TBL] [Abstract][Full Text] [Related]
5. Identification, isolation and characterization of process related impurities in ezetimibe.
Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
[TBL] [Abstract][Full Text] [Related]
6. Structural studies of racecadotril and its process impurities by NMR and mass spectroscopy.
Reddy KM; Babu JM; Sudhakar P; Sharma MS; Reddy GS; Vyas K
Pharmazie; 2006 Dec; 61(12):994-8. PubMed ID: 17283655
[TBL] [Abstract][Full Text] [Related]
7. Impurities in drugs IV: Indomethacin.
Curran NM; Lovering EG; McErlane KM; Watson JR
J Pharm Sci; 1980 Feb; 69(2):187-9. PubMed ID: 7359321
[TBL] [Abstract][Full Text] [Related]
8. Analysis of drug contamination from parabens in theophylline olamine.
Juenge EC; Gurka DF; Kreienbaum MA
J Pharm Sci; 1981 Jun; 70(6):589-93. PubMed ID: 7252796
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of impurities in docetaxel.
Vasu Dev R; Moses Babu J; Vyas K; Sai Ram P; Ramachandra P; Sekhar NM; Mohan Reddy DN; Srinivasa Rao N
J Pharm Biomed Anal; 2006 Feb; 40(3):614-22. PubMed ID: 16330175
[TBL] [Abstract][Full Text] [Related]
11. Isolation, characterization and determination of trace organic impurities in FD&C red no. 40.
Richfield-Fratz N; Baczynskyj WM; Miller GC; Bailey JE
J Chromatogr; 1989 Apr; 467(1):167-76. PubMed ID: 2753932
[TBL] [Abstract][Full Text] [Related]
12. Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.
Satyanarayana U; Rao DS; Kumar YR; Babu JM; Kumar PR; Reddy JT
J Pharm Biomed Anal; 2004 Jun; 35(4):951-7. PubMed ID: 15193741
[TBL] [Abstract][Full Text] [Related]
13. Impurities in illicit amphetamine: review.
Sinnema A; Verweij AM
Bull Narc; 1981; 33(3):37-54. PubMed ID: 7039749
[TBL] [Abstract][Full Text] [Related]
14. Impurities in drugs III: Trihexyphenidyl.
Poirier MA; Curran NM; McErlane KM; Lovering EG
J Pharm Sci; 1979 Sep; 68(9):1124-7. PubMed ID: 501534
[TBL] [Abstract][Full Text] [Related]
15. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
[TBL] [Abstract][Full Text] [Related]
16. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
[TBL] [Abstract][Full Text] [Related]
17. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
[TBL] [Abstract][Full Text] [Related]
18. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
[TBL] [Abstract][Full Text] [Related]
19. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
Görög S
Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
[TBL] [Abstract][Full Text] [Related]
20. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
